Barclays

Barclays’s Biote Corp. Warrant BTMDW Stock Holding History

Barclays’s Portfolio BTMDW Stock Details BTMDW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-52,450	Closed	-$29K	–	5391
2022 Q1	$29K	Buy	+52,450	New	+$24.9K	﹤0.01%	4321

Other funds holding BTMDW

LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return

Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Owl Creek Asset Management New York $1.38B AUM 59.67% 1-Year Est. Return

Balyasny Asset Management

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return

Silver Rock Financial Los Angeles, California $49.7M AUM 17.42% 1-Year Est. Return

Barclays's BTMDW Position: Q2 2022 in Review

Barclays sold out of Biote Corp. Warrant (BTMDW) in Q2 2022, closing a stake of 52,450 shares — an estimated $29K sold.

Barclays first reported a position in BTMDW in Q1 2022 and held it in 1 quarter. The position peaked at $29K in Q1 2022. 42 funds tracked by Wall St. Rank hold BTMDW as of Q2 2022.

Barclays reported no remaining Biote Corp. Warrant position as of Q2 2022 after selling out during the quarter.
Barclays sold 52,450 Biote Corp. Warrant shares in Q2 2022, an estimated $29K.
Barclays first reported a position in Biote Corp. Warrant in Q1 2022 and held it in 1 quarter.
Barclays's Biote Corp. Warrant position peaked at $29K in Q1 2022.
42 funds tracked by Wall St. Rank held Biote Corp. Warrant as of Q2 2022.

Based on Barclays's 13F filing for Q2 2022, filed 12 Aug 2022.